In addition, the impact of NANOG expression was greater in patients with lymph node metastasis than in node-negative patients, as was consistently demonstrated at both mRNA and protein levels using two large independent HNSCC cohorts. This evidence concerns the gene NANOG and metastatic malignant neoplasm in the lymph nodes.